AU2787495A - Use of copolymer-1 for the manufacture of a medicament for the treatment of optic neuritis - Google Patents

Use of copolymer-1 for the manufacture of a medicament for the treatment of optic neuritis

Info

Publication number
AU2787495A
AU2787495A AU27874/95A AU2787495A AU2787495A AU 2787495 A AU2787495 A AU 2787495A AU 27874/95 A AU27874/95 A AU 27874/95A AU 2787495 A AU2787495 A AU 2787495A AU 2787495 A AU2787495 A AU 2787495A
Authority
AU
Australia
Prior art keywords
medicament
copolymer
manufacture
treatment
optic neuritis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU27874/95A
Inventor
Anat Kesler
Edna Kott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of AU2787495A publication Critical patent/AU2787495A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
AU27874/95A 1994-06-06 1995-06-05 Use of copolymer-1 for the manufacture of a medicament for the treatment of optic neuritis Abandoned AU2787495A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9411292A GB9411292D0 (en) 1994-06-06 1994-06-06 Pharmaceuticals compositions
GB9411292 1994-06-06
PCT/EP1995/002125 WO1995033475A1 (en) 1994-06-06 1995-06-05 Use of copolymer-1 for the manufacture of a medicament for the treatment of optic neuritis

Publications (1)

Publication Number Publication Date
AU2787495A true AU2787495A (en) 1996-01-04

Family

ID=10756253

Family Applications (1)

Application Number Title Priority Date Filing Date
AU27874/95A Abandoned AU2787495A (en) 1994-06-06 1995-06-05 Use of copolymer-1 for the manufacture of a medicament for the treatment of optic neuritis

Country Status (8)

Country Link
EP (1) EP0767672A1 (en)
JP (1) JPH10500695A (en)
AU (1) AU2787495A (en)
CA (1) CA2192218A1 (en)
GB (1) GB9411292D0 (en)
IL (1) IL113992A0 (en)
WO (1) WO1995033475A1 (en)
ZA (1) ZA954469B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214791B1 (en) 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
WO2000005250A1 (en) 1998-07-23 2000-02-03 Yeda Research And Development Co., Ltd Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides
ES2527760T3 (en) 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Treatment of Crohn's disease with copolymer 1 and polypeptides
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
ZA200206457B (en) 2000-02-18 2003-08-13 Yeda Res & Dev Oral, nasal and pulmonary dosage formulations of copolymer 1.
PL363431A1 (en) * 2000-06-05 2004-11-15 Teva Pharmaceuticals Industries, Ltd. The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
US20020077278A1 (en) 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
WO2002076503A1 (en) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
WO2001097785A2 (en) * 2000-06-20 2001-12-27 Caprion Pharmaceuticals Inc. Basic copolymers for the treatment of prion-related-disease
AU2002353059B2 (en) 2001-12-04 2008-06-19 Teva Pharmaceutical Industries, Ltd. Processes for the measurement of the potency of glatiramer acetate
EP1807467B1 (en) 2004-10-29 2009-08-26 Sandoz AG Processes for preparing glatiramer

Also Published As

Publication number Publication date
EP0767672A1 (en) 1997-04-16
JPH10500695A (en) 1998-01-20
ZA954469B (en) 1996-01-24
WO1995033475A1 (en) 1995-12-14
GB9411292D0 (en) 1994-07-27
CA2192218A1 (en) 1995-12-14
IL113992A0 (en) 1995-10-31

Similar Documents

Publication Publication Date Title
AU3560495A (en) Medicament inhaler
AU5945296A (en) Medicament for nasal administration
AU5384096A (en) Use of vitamin D2 or vitamin D4-derivatives for the manufacture of a medicament for the treatment of secondary hyperparathyroidism
AU7005694A (en) Use of hydrophilic carotenoids for the manufacture of a medicament for the treatment of diseases having an oxygenation mechanism
ZA966319B (en) Corneal irrigation cannula
EP0755690A3 (en) Hypodermic cannula
AU7867994A (en) Hemofiltration of mediator-related diseases
AU6639096A (en) Corneal irrigation cannula
AU4048295A (en) Peptide medicaments for the treatment of disease
AU2844299A (en) Safety syringe for medical use
GB2279879B (en) Medicament inhalers
AU5801996A (en) Use of 1,2,4-triazole derivatives for the manufacture of a medicament for the treatment of cancers
EP0765663A3 (en) Use of dienogest for the manufacture of a medicament for the treatment of the skin by topical application
AU2787495A (en) Use of copolymer-1 for the manufacture of a medicament for the treatment of optic neuritis
AU4705193A (en) Medicaments for the treatment or prevention of elevated intraocular pressure
AU9173191A (en) Medicaments for the treatment of papillomavirus diseases
AU1116895A (en) Use of theophylline for the manufacture of a medicament for the treatment of asthma
AU3968695A (en) Patient operated tonometers
EP0765661A3 (en) Use of docosahexaenoic acid for the manufacture of a medicament for the treatment of glumerulonephritis
AU3684395A (en) Use of camptothecin or derivatives thereof for the manufacture of a medicament for the treatment of viral diseases
AU7982098A (en) Use of beta2-adrenoceptor agonists for the manufacture of a medicament for the treatment of scoliosis
ZA96722B (en) Combination therapy for hiv infection
AU7726796A (en) Use of 3-oxa-d-prostaglandins for the manufacture of a medicament for the treatment of glaucoma
AU5494298A (en) Pharmaceutical compositions for the treatment of the eye
AU2462097A (en) The use of a substance p antagonist for the manufacture of medicament for the treatment of ocular pain